title: First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor.
abstract: BACKGROUND
  Mobilization techniques for autologous peripheral blood stem cell (PBSC) collection include chemotherapy followed by hematopoietic growth factors, such as granulocyte colony-stimulating factor (G-CSF). Biosimilar versions of G-CSF are now available in Europe.
  
  
  METHODS
  In this study, 40 patients with a hematological malignancy scheduled to receive biosimilar G-CSF (Zarzio(®) Sandoz Biopharmaceuticals, Paris, France) following first-cycle chemotherapy for treatment and autologous PBSC mobilization were prospectively included at a single center. These patients were compared with a historical control group who had been treated with G-CSF (Neupogen(®) Paris, France) at the same center according to the same clinical protocol. PBSC harvesting was considered successful if at least 3×10(6) CD34+ cells/kg were collected. If three consecutive CD34+ tests were below 10/μL then PBSC harvesting was not performed.
  
  
  RESULTS
  Patient characteristics were similar in both groups with no significant differences in age, diagnosis, previous chemotherapy, or chemotherapy mobilization regimen. No significant differences were observed between groups in median CD34+ cells mobilized and collected, or the number of G-CSF injections and leukaphereses required to obtain the minimal CD34+ cell count. Proportion of failures was also similar in both groups.
  
  
  CONCLUSIONS
  Zarziois(®) comparable to Neupogen(®) for PBSC mobilization and collection after chemotherapy and so may provide a more cost-effective strategy.
authors.affiliation: Service de Biothérapie, Groupe Hospitalier Necker-Enfants Malades, Paris, France. francois.lefrere@nck.aphp.fr
authors.forename: François
authors.initials: F
authors.lastname: Lefrère
authors.forename: Anne-Colette
authors.initials: AC
authors.lastname: Brignier
authors.forename: Caroline
authors.initials: C
authors.lastname: Elie
authors.forename: Jean-Antoine
authors.initials: JA
authors.lastname: Ribeil
authors.forename: Michael
authors.initials: M
authors.lastname: Bernimoulin
authors.forename: Charbel
authors.initials: C
authors.lastname: Aoun
authors.forename: Liliane
authors.initials: L
authors.lastname: Dal Cortivo
authors.forename: Richard
authors.initials: R
authors.lastname: Delarue
authors.forename: Olivier
authors.initials: O
authors.lastname: Hermine
authors.forename: Marina
authors.initials: M
authors.lastname: Cavazzana-Calvo
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D000971:Antineoplastic Combined Chemotherapy Protocols; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D019337:Hematologic Neoplasms / Q000628:therapy; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods* / Q000592:standards; D006801:Humans; D007279:Injections, Subcutaneous; D007937:Leukapheresis / Q000592:standards; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D011994:Recombinant Proteins; D012107:Research Design; D014182:Transplantation, Autologous / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim